THE STUFF THAT human health care LEADERS ARE MADE OF

Tatsuyuki Yasuno serves as Chairman & Chief Executive Officer (CEO) of Eisai Inc., in addition to holding the role of President of the Americas Region. In these positions, he is responsible for the strategic direction of the company in North America, which is the largest commercial region for Eisai globally. Mr. Yasuno has full operating responsibility for the management of Eisai’s operating companies and sites in the United States and Canada, including its fully integrated commercial and medical organizations specializing in oncology and neurology, as well as multiple research and development facilities, and the supply chain organization. He has served as a Corporate Officer, Senior Vice President, of Eisai Co., Ltd., the parent company of Eisai Inc., since 2016.

Since joining Eisai in 1991, Mr. Yasuno has held a number of key executive roles in Japan, Europe and the United States. Most recently, he served as Chief Financial Officer and Chief Investor Relations Officer of Eisai Co., Ltd. in Tokyo from June 2022 to August 2023.

Mr. Yasuno joined the company as a Medical Sales Representative. During his early career, he held various positions of increasing responsibility in the Corporate Planning Department, and was appointed assistant to Global CEO Haruo Naito, a position he held for two years.

After obtaining his Master of Business Administration (MBA) degree in the U.S., Mr. Yasuno returned to Japan and worked in the Investor Relations Department. A year later, he was promoted to Director, Head of the Executives Offices. In 2009, he was named Director of European Business Strategy and transferred to the European headquarters in Hatfield, United Kingdom. He was subsequently appointed Executive Director of Eisai Value Maximization Systems, the company’s global marketing and medical unit, in 2011, located in the U.S. headquarters in New Jersey.

From 2014 through 2019, Mr. Yasuno held various roles in Tokyo, leading key functional areas that included Corporate Planning & Strategy, Global Business Coordination, and Global Partnership Development. As Vice President, Global Partnership Development, he executed the company’s strategic alliance with Merck in 2018. In 2020, Mr. Yasuno returned to the U.S. as President of Eisai Inc. and the Americas Region, successfully navigating the business and leading the organization through the critical pandemic period. He relocated the company to its new U.S. headquarters in Nutley, NJ in 2021 and managed re-entry of the workforce to the new facility.

Mr. Yasuno earned his Bachelor of Political Science degree from Waseda University in Tokyo, Japan. He received his MBA from the Kellogg School of Management at Northwestern University.

Dr. Owa is responsible for all discovery research and oversight of clinical development for the company’s oncology business.

Since joining Eisai as a scientist in the Cancer Research Division in 1991, Dr. Owa has assumed positions of increasing responsibility within the R&D operations. He specializes in anticancer research, including drug discovery and the development of sulfonamide anticancer agents, as well as target and biomarker identification of novel anticancer small molecules.

Dr. Owa received his Ph.D. in Organic Chemistry, Medicinal Chemistry and Cancer Chemistry from the University of Tokyo, with a focus on chemistry and biology of naturally-occurring and manmade bleomycins. In addition, he completed a two-year, post-doctoral fellowship in the Department of Chemistry and Chemical Biology at Harvard University.

Lynn D. Kramer, M.D., FAAN, is Chief Clinical Officer, DHBL (Deep Human Biology Learning) at Eisai and a member of the Eisai Co., Ltd. Executive Committee. In these roles, he oversees the product creation cycle, including clinical introduction and regulatory approval of innovative projects for all Eisai products.

Dr. Kramer, who has been with Eisai since 2007, started as the Executive Vice President of Global Clinical Research, and was soon promoted to the additional role of Chief Operating Officer of Eisai Medical Research. In early 2009, he was named President of the Scientific and Operational Clinical Support Core Function Unit (SOCS CFU) and President of the Neuroscience, Product Creation Unit. He was named Chief Clinical Officer and a member of the Executive Committee, Eisai Company, Ltd. in 2012. In these functions he has been responsible for all functions including regulatory, biostatistics, data management, medical writing, clinical functions and clinical pharmacology and modeling and simulations. During this time, he has overseen the development and regulatory approval of several new molecular entities.

Earlier in his career, he held senior positions in drug development including serving as Vice President Clinical Research and Head of the Therapeutic Area Strategy Team at Novartis, and Vice President Clinical Research at the R.W. Johnson Pharmaceutical Research Institute. Prior to his industry career he was Co-PI of an National Institutes of Health (NIH) sponsored epilepsy-focused program project in Los Angeles, California.

Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He previously served as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) and on the Board of Directors at American Society for Experimental Neuro Therapeutics (ASENT). He currently is a member of the Pharma R&D Leadership Forum. In 2022, he became the 12th recipient of the 2022 Epilepsy Foundation’s Lifetime Accelerator Award.

Dr. Kramer received his M.D. from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia.

Alexander Scott oversees all the functional departments of the company’s regional corporate services operations, including Advocacy, Compliance, Corporate Communications, Legal, Finance, Human Resources, Internal Audit, Information Technology and Product Safety. Alex serves as a trustee of the Eisai USA Foundation, the company’s philanthropic arm and as a member of the America's Executive Committee.

Since joining Eisai in 1992, Alex has helped craft the company’s U.S. globalization strategy and establish a commercial infrastructure through a variety of roles in Commercial Planning, Corporate Strategy, Business Development and Alliance Management. He has negotiated global alliances with a number of companies and played a key role in establishing business collaborations with more than 25 pharmaceutical companies. He also managed Eisai’s acquisitions of MGI PHARMA, INC. and Morphotek, Inc.

Alex holds a Bachelor of Arts in Government from Wesleyan University and a Master of Business Administration degree from Duke University. He is a member of the Licensing Executives Society, and serves as Treasurer and a Board Member of Gilda’s Club New York City.

With close to 30 years of experience in the pharmaceutical industry, Paul Hawthorne leads the Commercial, Medical Affairs and Market Access organizations for Eisai U.S. and Canada Oncology and Neurology portfolios. Paul and his teams are responsible for the development and implementation of our commercialization, data generation, data dissemination and access strategies that enable Eisai to fulfill its PURPOSE, our human health care (hhc) mission. Paul also serves as a member of the Americas Executive Committee.

In April 2016, Paul joined Eisai with the initial goal of creating and driving commercial strategies for the company’s Neurology portfolio, before being promoted to Chief Commercial Officer in January 2019 and then to his current role in December 2019.

Prior to Eisai, he spent 25 years with Sanofi, where he held senior leadership positions of increasing responsibility across all therapeutic areas.

Paul holds a Master of Business Administration in Marketing from LaSalle University. He earned his undergraduate degree from the University of Pittsburgh.

Katsuya Haruna serves as Group Officer & Executive Vice President, U.S. Business Operations at Eisai Inc. In this corporate executive role, he oversees the Sales and Marketing and Market Access functions, and separately, the Medical Affairs function for the company’s Oncology and Neurology operations in the U.S.

From a global perspective, he oversees all sales and marketing for oncology products and is Oncology Pipeline Global Lead Deep Human Biology Learning (DHBL).

Mr. Haruna, who joined Eisai in 2008 as a sales representative, has attained roles of increasing responsibility over his 15+ year tenure with the company. In late 2019, he was transferred to the U.S. to become Vice President, Co-Global Brand Lead for an FDA-approved oncology product. In this role, he provided strategic guidance and support for the launch of a combination product as part of Eisai’s Alliance Agreement with another company. In June 2021, Mr. Haruna assumed the additional role of leading the U.S. Oncology Marketing team and was soon after also appointed Vice President, U.S. Oncology Commercial & Alliance Lead. He was promoted to Senior Vice President and appointed LENVIMA & Oncology Pipeline Global Lead in July 2023, and assumed responsibility for the company’s Global Oncology Portfolio in addition to his U.S. responsibilities. He was elevated to his current role of Executive Vice President, US Business Operations in April 2024.

Mr. Haruna received a Bachelor’s Degree in Pharmaceutical Sciences from Hoshi University in Japan.

Yasutaka Yoshida is responsible for evaluating, managing and executing the strategic initiatives and market opportunities that support Eisai’s short-term and long-term planning and strategies, including operational investments, capital expansions, strategic alliances and partnerships, acquisitions and divestitures.

Mr. Yoshida, who joined Eisai in 2004 as a Medical Sales Representative, has held a variety of diverse roles of increasing responsibility during his tenure with the company. Prior to being appointed to his current role in July 2020, Mr. Yoshida spent two years working in the company’s Executive Office in Japan. In June 2019, he was promoted to Senior Director of the CEO Office, a role in which he directly supported the company’s global CEO, Dr. Haruo Naito. He has relocated to the company’s U.S. headquarters in Nutley, N.J. Before working in the Executive Office, he served two years as Associate Director of the Corporate Planning and Strategy Department, acting as the liaison between the Americas region and the global headquarters to assist in the development of the company’s strategy and financial planning. Earlier in his career, Mr. Yoshida spent four years as Manager of the Government Affairs Department, in which he worked with the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) and was a management member on Japan Pricing Policy. He also spent two years as Associate Manager in the Human Resources Department, and served two years as Associate Manager at the Japan Business Headquarters after his promotion from a Medical Sales Representative.

Mr. Yoshida holds of Bachelor of Law degree from Kobe University, and an English Language degree from the Kansai Gaidai University in Japan.

Neriman Botas serves as Executive Vice President, Human Resources. In this role, she works with Eisai's business leaders to identify priorities, align resources and cultivate a culture that enables all employees to thrive at the company. Neriman is a member of the Americas Executive Committee, as well as a trustee of the Eisai USA Foundation, the company’s philanthropic arm.

Since joining the company in 2004, Neriman has led the Human Resources organization in the design and deployment of progressive talent management practices that promote growth, accountability and empowerment. Prior to joining Eisai, Neriman spent 19 years at Schering-Plough Corporation, where she developed her human resources career in roles spanning all business segments, including both U.S. and global responsibilities.

Neriman received her Bachelor of Arts in psychology from Douglass College of Rutgers University in New Jersey. She also completed the Executive Human Resources Development Program at Cornell University School of Industrial and Labor Relations.

Brian Harraka serves as Vice President and Chief Financial Officer of Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd. In this position, he is responsible for leading all aspects of Finance and Accounting, Strategic Procurement and Site Services. He is also a member of the company’s Executive Committee for the Americas, as well as its Global Finance and Accounting Board.

Since joining Eisai as Corporate Controller in 2019, Mr. Harraka has been instrumental in leading technology and automation initiatives as well as the design and implementation of enhanced financial processes for the company’s sites in the United States, Canada, Mexico and Brazil. He was promoted to Deputy Chief Financial Officer in March 2022, a role he held until being named to his current position in April 2024.

Prior to Eisai, Mr. Harraka spent 13 years at Novartis, where he held several roles of increasing responsibility within the Accounting and Finance departments. In his last position there, he served as Executive Director of Accounting, leading the company’s accounting operations for the US Pharmaceuticals and Generics business. Earlier in his career, Mr. Harraka worked at Reckitt Benckiser and KPMG.

Mr. Harraka earned his Bachelor of Science degree in Accounting from Montclair State University. He is a Certified Public Accountant (CPA) in the State of New Jersey, as well as a Chartered Global Management Accountant (CGMA).

Vincent Andrews leads Eisai's Legal Department and the Ethics & Compliance Department. Vince provides strategic executive oversight on Legal Matters, the Corporate Compliance Program and manages day-to-day Legal and Compliance operations, as well as Product Security. Over the past 16 plus years at Eisai, Vince has led or overseen several key areas for Legal‚ including Life Sciences Transactions‚ Alliance Management, Intellectual Property, and Eisai's litigation and investigations. Vince serves a member of the Americas Executive Committee, the Global Risk Management Committee and the Global Product Security Committee.

Prior to joining Eisai‚ Vince served as Assistant General Counsel to Eyetech Pharmaceuticals‚ a successful biotech start-up‚ and as Associate General Counsel to MIM Corporation in Elmsford‚ NY‚ a publicly-traded specialty pharmaceutical distributor and pharmaceutical benefit manager. In addition‚ Vince spent over five years at Schulte Roth & Zabel, advising private and public companies on corporate transactions‚ securities issuances and filings and general corporate matters.

Vince received his Juris Doctor degree from the Northeastern University School of Law. He earned his Bachelor of Arts degree in Political Science from Binghamton University.

Teresa Cronin serves as Vice President of Corporate Communications and Patient Advocacy at Eisai Inc. In this role, she is responsible for cultivating and maintaining Eisai’s corporate reputation through strategic communications and patient advocacy activities. She also serves as a member of the company’s Executive Committee for the Americas, and represents Eisai on multiple Corporate Councils.

Ms. Cronin, who has 20 years of experience as a marketer and public relations professional in the branded pharmaceutical and consumer health care markets, most recently served as Executive Director of Corporate Advocacy. In this position, she led the implementation of strategies with the objective of building and maintaining strong relationships with patient and professional organizations to advocate, enhance and promote initiatives that support Eisai’s human health care (hhc) mission. She was also responsible for the development of disease awareness campaigns with patient advocacy organizations that aim to address unmet patient needs within the company’s therapeutic areas of focus.

Upon joining Eisai in 2012 as Associate Director of Public Relations, Ms. Cronin led the strategic and tactical implementation of several programs to support Eisai’s oncology and neurology franchises. She also served as the hhc mission administrator for the Americas region from 2012-2016, in which she and her team were responsible for the creation of over 500 initiatives that enable employees to have direct interactions with patients. Through these events, the company believes employees can develop a much better understanding of patients, and thus bring these learnings back to their jobs. Ms. Cronin was promoted to Director of Corporate Advocacy in 2016.

Programs developed at Eisai under Ms. Cronin’s leadership include Magnolia™, a patient advocacy program designed to give patients living with cancer a way to address their challenges. The first initiative under Magnolia™, Magnolia Meals at Home™ provides free meals to patients and families living with breast and thyroid cancer. Magnolia™ has been expanded to include Meal Train Sponsored By Magnolia^®, an online calendar that aims to optimize the impact of meal delivery to patients and families living with breast cancer, as well as Magnolia Paws for Compassion^®, which increases access to animal assistance and the benefits that these animals can provide to those coping with illness. Other initiatives created by Ms. Cronin include #ThisisMBC, Teens for Pink, Myths and Truths about Thyroid Cancer™, Time to Talk CINV™ and My Healthy™.

Prior to joining Eisai, Ms. Cronin spent seven years at GSW Worldwide, an advertising agency that specializes in launching pharmaceutical brands in vaccines, epilepsy, women’s health and dental care.

Ms. Cronin earned her Bachelor’s Degree from Iona College in Business Management & Marketing.

Rene Rancourt is responsible for leading the information technology function for Eisai’s Americas region, and developing the strategy for IT functions, including systems design and analysis, applications and systems programming, database management, and data processing operations.

Having worked at Sanofi in France and in different capacities in the United States, Rene’s depth of knowledge and 20+ experience is showcased by the variety of roles he has held including project management, solution architecture, system integration, infrastructure and operations, and data analytics. In addition to his IT expertise, Rene has also held business leadership positions, including Clinical transformational program leader, R&D site director and Clinical Supply Chain Quality head. Known for his cost-saving and business oriented technological solutions, innovative ideas and ability to drive growth and transform, Rene is an effective change agent.

After leaving Sanofi, Rene served as the interim CIO for Brancher Inks and co-founded a start-up as the CTO.

Most recently, he was the Global Head of IT at Ichnos Sciences, a biotech company focused on immuno-oncology. While at Ichnos, he built an IT strategy supporting the company’s shift from start-up to growth mode.

Rene has a Master of Science Degree in Computer Science, Thermo-Dynamics from Ecole Nationale Superieure des Mines de Nancy, in France. He holds various certifications, including Amazon Web Services (AWS) Certified Cloud Practitioner, Microsoft Azure Fundamentals and Machine Learning from Stanford.